Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.

Garrison LP Jr, Lubeck D, Lalla D, Paton V, Dueck A, Perez EA.

Cancer. 2007 Aug 1;110(3):489-98.

2.

[Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].

Macedo A, Monteiro I, Andrade S, Cirrincione A, Ray J.

Acta Med Port. 2010 May-Jun;23(3):475-82. Epub 2010 Jun 14. Review. Portuguese.

3.

Trastuzumab: a pharmacoeconomic review of its use in early breast cancer.

McKeage K, Lyseng-Williamson KA.

Pharmacoeconomics. 2008;26(8):699-719. Review.

PMID:
18620462
4.

Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.

Chan AL, Leung HW, Lu CL, Lin SJ.

Ann Pharmacother. 2009 Feb;43(2):296-303. doi: 10.1345/aph.1L504. Epub 2009 Feb 3. Review. Erratum in: Ann Pharmacother. 2009 Mar;43(3):551.

PMID:
19193576
5.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

6.

Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.

Norman G, Rice S, Spackman E, Stirk L, Danso-Appiah A, Suh D, Palmer S, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:33-42. doi: 10.3310/hta15suppl1/04. Review.

7.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

8.

Role of trastuzumab in adjuvant therapy for locally invasive breast cancer.

Kabe KL, Kolesar JM.

Am J Health Syst Pharm. 2006 Mar 15;63(6):527-33. Review.

PMID:
16522889
9.

Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.

Knight C, Hind D, Brewer N, Abbott V.

Health Technol Assess. 2004 Sep;8(37):iii, ix-xi, 1-82. Review.

10.

Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.

Lee JA, Shaheen M, Walke T, Daly M.

Expert Rev Pharmacoecon Outcomes Res. 2011 Jun;11(3):325-41. doi: 10.1586/erp.11.25. Review.

PMID:
21671702
11.
12.

Trastuzumab treatment of early stage breast cancer is cost-effective from the perspective of the Belgian health care authorities.

Van Vlaenderen I, Canon JL, Cocquyt V, Jerusalem G, Machiels JP, Neven P, Nechelput M, Delabaye I, Gyldmark M, Annemans L.

Acta Clin Belg. 2009 Mar-Apr;64(2):100-12. Review.

PMID:
19432022
13.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Jahanzeb M.

Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.

PMID:
18757259
14.

Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S.

Oncologist. 2008 Jun;13(6):620-30. doi: 10.1634/theoncologist.2008-0001. Review.

15.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
16.

Trastuzumab for early breast cancer: current status and future directions.

Dinh P, de Azambuja E, Piccart-Gebhart MJ.

Clin Adv Hematol Oncol. 2007 Sep;5(9):707-17. Review.

PMID:
17982412
17.

Facts and controversies in the use of trastuzumab in the adjuvant setting.

Dinh P, de Azambuja E, Cardoso F, Piccart-Gebhart MJ.

Nat Clin Pract Oncol. 2008 Nov;5(11):645-54. doi: 10.1038/ncponc1219. Epub 2008 Sep 9. Review.

PMID:
18779850
18.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.

PMID:
22015286
19.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
20.

[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].

Vos EJ, Linn SC, Rodenhuis S.

Ned Tijdschr Geneeskd. 2006 Apr 8;150(14):776-80. Review. Dutch.

PMID:
16649394

Supplemental Content

Support Center